June 18, 2013
- Deerfield, Ill., June 17, and Osaka, Japan, June 18, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NESINA (alogliptin) and the fixed-dose combination therapies KAZANO (alogliptin and metformin
June 13, 2013
- Osaka, Japan, June 13, 2013 --- Takeda Pharmaceutical Company Limited (Takeda) today announced $2.15 billion settlement reached with Teva Pharmaceutical Industries Limited (Teva) and Sun Pharmaceutical Industries Limited (Sun) for patent-infringement damages resulting from their "at-risk&rd
June 10, 2013
- Pfizer Japan Inc. (Head office: Shibuya-ku, Tokyo; “Pfizer”) and Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; “Takeda”) jointly announced that both parties launch on June 10, 2013 Enbrel® Subcutaneous Injection 50mg Pen 1.0mL, a
June 5, 2013
- Osaka Japan, June 5, 2013—Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it will start using bio-polyethylene bottles (hereafter “Bio-PE bottles”) as the primary packaging* container for the hypertension treatment product, Azil
June 4, 2013
- This ongoing study evaluated MLN9708 in 60 MM patients who had received two or more prior therapies. The primary objectives were to determine the safety, tolerability and MTD of once a week MLN9708. Results from the dose-escalation and expansion cohorts presented by Shaji Kumar, M.D., incl
June 3, 2013
- Chicago, IL., June 1, 2013 and Osaka, Japan, June 3, 2013 – Takeda Pharmaceutical Company Limited (TSE:4502) today announced interim data from a Phase 1/2, open-label, multicenter study with ADCETRIS®(brentuximab vedotin) in pediatric patients diagnosed with CD30-positive relapsed
May 21, 2013
- Osaka, Japan, May 21, 2013--- Takeda Pharmaceutical Company Limited today announced new appointment of senior leadership. The details are as follows;
May 20, 2013
- San Francisco, California – May 18, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of dep
May 16, 2013
- Osaka, Japan, May 16, 2013 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today the results of a Phase III clinical trial (CCT-003) of fasiglifam (Development code:TAK-875) for the treatment of type 2 diabetes presented at the 56th Annual Meeting of the Japan Diabetes Socie
May 9, 2013
- Osaka, Japan, May 9, 2013 --- Takeda Pharmaceutical Company Limited (“Takeda”, “the Company”) today announced its “Vision 2020,” and commenced its Mid-Range Growth Strategy starting from fiscal 2013 that aims to realize where the company as